PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients.
Published version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Giardiello, Daniele
Hooning, Maartje J
Hauptmann, Michael
Keeman, Renske
Heemskerk-Gerritsen, B A M
Abstract
Background
Prediction of contralateral breast cancer (CBC) risk is challenging due to moderate performances of the known risk factors. We aimed to improve our previous risk prediction model (PredictCBC) by updated follow-up and including additional risk factors.Methods
We included data from 207,510 invasive breast cancer patients participating in 23 studies. In total, 8225 CBC events occurred over a median follow-up of 10.2 years. In addition to the previously included risk factors, PredictCBC-2.0 included CHEK2 c.1100delC, a 313 variant polygenic risk score (PRS-313), body mass index (BMI), and parity. Fine and Gray regression was used to fit the model. Calibration and a time-dependent area under the curve (AUC) at 5 and 10 years were assessed to determine the performance of the models. Decision curve analysis was performed to evaluate the net benefit of PredictCBC-2.0 and previous PredictCBC models.Results
The discrimination of PredictCBC-2.0 at 10 years was higher than PredictCBC with an AUC of 0.65 (95% prediction intervals (PI) 0.56-0.74) versus 0.63 (95%PI 0.54-0.71). PredictCBC-2.0 was well calibrated with an observed/expected ratio at 10 years of 0.92 (95%PI 0.34-2.54). Decision curve analysis for contralateral preventive mastectomy (CPM) showed the potential clinical utility of PredictCBC-2.0 between thresholds of 4 and 12% 10-year CBC risk for BRCA1/2 mutation carriers and non-carriers.Conclusions
Additional genetic information beyond BRCA1/2 germline mutations improved CBC risk prediction and might help tailor clinical decision-making toward CPM or alternative preventive strategies. Identifying patients who benefit from CPM, especially in the general breast cancer population, remains challenging.Description
Keywords
Clinical Decision-making, Risk Prediction, Contralateral Breast Cancer, Polygenic Risk Score, Prediction Performance, Bcac, Breast Cancer Association Consortium, Brca1/2 Germline Mutation, Contralateral Preventive Mastectomy, Breast Cancer Genetic Predisposition, Humans, Breast Neoplasms, Mastectomy, Risk Factors, Germ-Line Mutation, Female, Prophylactic Mastectomy
Journal Title
Breast cancer research : BCR
Conference Name
Journal ISSN
1465-5411
Volume Title
24
Publisher
Publisher DOI
Sponsorship
CDC HHS (NU58DP006320)
NCI NIH HHS (R01 CA054281, R01 CA163353, UM1 CA164920, HHSN261201800016I, U01 CA098758, R01 CA132839, R01 CA063464, U01 CA164973)
NCI NIH HHS (R01 CA054281, R01 CA163353, UM1 CA164920, HHSN261201800016I, U01 CA098758, R01 CA132839, R01 CA063464, U01 CA164973)